Prognosis of Sporadic Resected Small (≤ 2 cm) Nonfunctional Pancreatic Neuroendocrine Neoplasms - A Multi-Institutional Study Abstract #1897

Introduction: Malignant potential of sporadic nonmetastatic nonfunctional pancreatic neuroendocrine tumors (sNF-PNET) is difficult to preoperatively predict
Aim(s): To assess the prognosis of resected (≤ 20 mm) sNF-PNET
Materials and methods: Patients with resected sNF-PNET were identified from databases of 16 European surgical centers. Postoperative outcomes as well as, risk factors for recurrence were identified by uni- and multivariate analyses
Conference: 14th Annual ENETS conference (2017)
Category: Surgical treatment
Presenting Author: Pr Sebastien Gaujoux
Keywords: pancreatic NETs

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1908 Staging Classification Comparison of Resected Pancreatic Neuroendocrine Tumors (pNETs) Utilizing the National Cancer Database (NCDB)
Introduction: The staging classification of pNETs remains a matter of debate and no obvious superior system has emerged.
Conference: 14th Annual ENETS conference (2017)
Category: Pathology, grading, staging
Presenting Author: Gustavo Westin
#214 Comparison of the AJCC and ENETS Staging Classifications for Neuroendocrine Tumors of the Pancreas
Introduction: The AJCC Cancer Staging Manual (7th edition, 2010) has introduced a novel TNM staging classification for pancreatic NETs. This classification has not yet been validated.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Jonathan Strosberg
#1191 Efficacy of Lanreotide versus Follow-up in Early-stage Duodeno-Pancreatic Neuroendocrine Tumors (NETs) Related to Multiple Endocrine Neoplasia Type 1 (MEN1): Preliminary Data
Introduction: Surgery is the only curative approach for NETs, representing the first-line therapy. As most pts with MEN1 have multiple duodeno-pancreatic NETs, cure is generally not possible, unless to adopt radical surgery. Somatostatin analogues (SSAs) represent one of the main therapeutic option in functioning well-differentiated NETs. There are no perspective studies focusing on MEN1-related NETs.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: DR. Valeria Ramundo
#83 Surgical treatment of duodenopancreatic neuroendocrine tumors (pNETs) in patients with multiple endocrine neoplasia type 1 (MEN 1): a Dutch consensus statement
Introduction: Duodenopancreatic neuroendocrine tumors (pNETs) in multiple endocrine neoplasia type 1 (MEN 1) are the most important cause of MEN 1-related death. Surgery is the only curative treatment, but controversy exists on the optimal strategy. Recent guidelines on pNETs have limited recommendations specific for MEN 1. Therefore, a Dutch multidisciplinary consensus meeting was organized.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Carolina RC Pieterman
#1521 Metastatic Disease in Gastroenteropancreatic Neuroendocrine Cancer: Incidence, Treatment and Survival
Introduction: Data on patients with metastatic disease from GEP-NETs are rare.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Ariana Madani